SG11201504469XA - Therapeutic cd47 antibodies - Google Patents

Therapeutic cd47 antibodies

Info

Publication number
SG11201504469XA
SG11201504469XA SG11201504469XA SG11201504469XA SG11201504469XA SG 11201504469X A SG11201504469X A SG 11201504469XA SG 11201504469X A SG11201504469X A SG 11201504469XA SG 11201504469X A SG11201504469X A SG 11201504469XA SG 11201504469X A SG11201504469X A SG 11201504469XA
Authority
SG
Singapore
Prior art keywords
antibodies
therapeutic
Prior art date
Application number
SG11201504469XA
Inventor
William A Frazier
Pamela T Manning
Gerhard Frey
Hwai Wen Chang
Original Assignee
Vasculox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasculox Inc filed Critical Vasculox Inc
Publication of SG11201504469XA publication Critical patent/SG11201504469XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11201504469XA 2012-12-12 2013-12-12 Therapeutic cd47 antibodies SG11201504469XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261736301P 2012-12-12 2012-12-12
US201361833691P 2013-06-11 2013-06-11
PCT/US2013/074766 WO2014093678A2 (en) 2012-12-12 2013-12-12 Therapeutic cd47 antibodies

Publications (1)

Publication Number Publication Date
SG11201504469XA true SG11201504469XA (en) 2015-07-30

Family

ID=50935081

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504469XA SG11201504469XA (en) 2012-12-12 2013-12-12 Therapeutic cd47 antibodies

Country Status (16)

Country Link
US (4) US20140363442A1 (en)
EP (1) EP2931751B1 (en)
JP (1) JP6572131B2 (en)
KR (1) KR20150093770A (en)
CN (1) CN105102479B (en)
AU (1) AU2013359167B2 (en)
BR (1) BR112015013431A2 (en)
CA (1) CA2894439A1 (en)
ES (1) ES2786083T3 (en)
HK (1) HK1216647A1 (en)
IL (1) IL239339A0 (en)
MX (1) MX2015007446A (en)
PH (1) PH12015501318A1 (en)
RU (1) RU2015122228A (en)
SG (1) SG11201504469XA (en)
WO (2) WO2014093678A2 (en)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3054220C (en) 2008-01-15 2022-10-11 The Board Of Trustees Of The Leland Stanford Junior University Methods for manilpulating phagocytosis mediated by cd47
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
KR20150093770A (en) 2012-12-12 2015-08-18 베스쿨럭스 인코포레이티드 Therapeutic cd47 antibodies
PT2931752T (en) 2012-12-17 2019-11-20 Trillium Therapeutics Inc Treatment of cd47+ disease cells with sirp alpha-fc fusions
EP3936145A1 (en) * 2014-07-31 2022-01-12 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
EP3204420B1 (en) 2014-10-10 2020-09-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods to eliminate cancer stem cells by targeting cd47
CA2967379A1 (en) * 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
EP4296278A3 (en) 2014-12-05 2024-03-27 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 47 gene
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
CN107921121B (en) * 2015-03-04 2022-02-08 索伦托药业有限公司 Antibody therapeutics that bind CD47
CN104804093A (en) * 2015-05-27 2015-07-29 江苏春申堂药业有限公司 Single-domain antibody for CD47
WO2017035480A1 (en) 2015-08-26 2017-03-02 The Board Of Trustees Of The Leland Stanford Junior University Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist
US10221249B2 (en) * 2015-09-10 2019-03-05 Affigen, Llc Method of making patient specific anti-idiotype antibodies
EP3349787A4 (en) 2015-09-18 2019-03-27 Arch Oncology, Inc. Therapeutic cd47 antibodies
GB2558131B (en) 2015-09-21 2021-05-19 Surface Oncology Inc Anti-CD47 antibodies and methods of use
EP3380117B1 (en) 2015-11-27 2021-01-06 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
JP7227007B2 (en) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド Antibodies specific for glycosylated BTLA (B- and T-lymphocyte-attenuating factor)
ES2796378T3 (en) 2016-01-11 2020-11-26 Forty Seven Inc Humanized, mouse, or chemical anti-cd47 monoclonal antibodies
US20170210803A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents
EP3442593A4 (en) * 2016-04-15 2020-01-01 Trillium Therapeutics Inc. Macrophage stimulation in cd47 blockade therapy
CN106084052B (en) 2016-06-17 2019-12-27 长春金赛药业股份有限公司 anti-CD 47 monoclonal antibody and application thereof
CN106117354B (en) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 Whole-molecule IgG antibody of fully human anti-CD 47 and application thereof
US11618784B2 (en) 2016-07-19 2023-04-04 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD47 combination therapy
CN114773471A (en) 2016-10-20 2022-07-22 天境生物科技(上海)有限公司 Novel CD47 monoclonal antibody and application thereof
WO2018075960A1 (en) * 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
WO2018081897A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
TW201819413A (en) * 2016-11-28 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 CD47 antibody, antigen-binding fragments and pharmaceutical use thereof
EP3345924A1 (en) * 2017-01-10 2018-07-11 Universität Duisburg-Essen Use of cd47 antibodies
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CA3051512A1 (en) * 2017-01-26 2018-08-02 Zlip Holding Limited Cd47 antigen binding unit and uses thereof
EP3601351A1 (en) * 2017-03-27 2020-02-05 Celgene Corporation Methods and compositions for reduction of immunogenicity
WO2018176132A1 (en) * 2017-03-28 2018-10-04 Trillium Therapeutics Inc. Cd47 blockade therapy
WO2019014398A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
KR102646468B1 (en) 2017-08-02 2024-03-11 페인스 테라퓨틱스 인코포레이티드 Anti-CD47 antibodies and uses thereof
WO2019034895A1 (en) * 2017-08-18 2019-02-21 Ultrahuman Four Limited Binding agents
CN109422811A (en) * 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 Anti-cd 47 antibody and application thereof
EA039662B1 (en) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Antibodies specific to cd47 and pd-l1
US11802153B2 (en) 2017-10-18 2023-10-31 Forty Seven, Inc. Anti-CD47 agent-based ovarian cancer therapy
AU2018358004A1 (en) 2017-11-01 2020-05-28 Hummingbird Bioscience Pte. Ltd. CD47 antigen-binding molecules
WO2019090355A1 (en) * 2017-11-06 2019-05-09 Children's National Medical Center Cells expressing antibodies and methods of treatment using the same
WO2019084692A1 (en) * 2017-11-06 2019-05-09 Trillium Therapeutics Inc. Cd47 blockade with radiation therapy
JP7391845B2 (en) 2017-12-01 2023-12-05 シージェン インコーポレイテッド CD47 antibodies and their use to treat cancer
CN110144009B (en) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 CD47 single domain antibodies and uses thereof
CN110305212A (en) * 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 Anti-cd 47 antibody and application thereof
US20210155691A1 (en) * 2018-04-16 2021-05-27 Adaerata, Limited Partnership Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers
CN108484770B (en) * 2018-05-16 2020-11-13 武汉云克隆科技股份有限公司 Recombinant rat anti-mouse CD4 monoclonal antibody, preparation method and application
CN110538321B (en) * 2018-05-29 2023-03-10 江苏恒瑞医药股份有限公司 CD47 antibody pharmaceutical composition and application thereof
CN112566662A (en) 2018-06-15 2021-03-26 阿库鲁斯生物科学公司 Blocking antibodies against CD47 and methods of use thereof
CN110615841B (en) * 2018-06-20 2022-01-04 瑞阳(苏州)生物科技有限公司 Anti-human CD47 monoclonal antibody and application thereof
JP7340591B2 (en) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド Genetically engineered immunostimulatory bacterial strains and their uses
US20210324075A1 (en) * 2018-08-13 2021-10-21 Arch Oncology, Inc. Therapeutic cd47 antibodies
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2020043188A1 (en) * 2018-08-31 2020-03-05 南京圣和药业股份有限公司 Anti-cd47 antibody and application thereof
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
WO2020114399A1 (en) * 2018-12-03 2020-06-11 上海开拓者生物医药有限公司 Cd47 antibody, preparation method therefor and uses thereof
EP3936526A4 (en) 2019-03-06 2023-03-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Bifunctional fusion protein and pharmaceutical use thereof
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
WO2020247820A1 (en) 2019-06-07 2020-12-10 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
WO2020253785A1 (en) * 2019-06-19 2020-12-24 Lepu Biopharma Co., Ltd. Anti-cd47 antibodies and uses thereof
KR20220024211A (en) 2019-06-19 2022-03-03 레푸 바이오파마 컴퍼니 리미티드 Anti-CD47 Antibodies and Their Uses
AU2020315598A1 (en) 2019-07-16 2022-03-03 Gilead Sciences, Inc. HIV vaccines and methods of making and using
MX2022002613A (en) 2019-09-03 2022-06-02 Myeloid Therapeutics Inc Methods and compositions for genomic integration.
AU2020342192A1 (en) * 2019-09-03 2022-04-21 Akeso Biopharma, Inc Anti-CD47 monoclonal antibody and use thereof
KR20220085796A (en) 2019-10-18 2022-06-22 포티 세븐, 인코포레이티드 Combination Therapy to Treat Myelodysplastic Syndrome and Acute Myelogenous Leukemia
US20220403023A1 (en) * 2019-10-25 2022-12-22 WuXi Biologics Ireland Limited Novel anti-cd47 antibodies and uses thereof
US20210147568A1 (en) 2019-10-31 2021-05-20 Forty Seven, Inc. Anti-cd47 based treatment of blood cancer
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
MX2022007598A (en) 2019-12-20 2022-09-23 Instil Bio Uk Ltd Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof.
EP4081305B1 (en) 2019-12-24 2024-09-18 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
CN115087488A (en) 2020-02-14 2022-09-20 震动疗法股份有限公司 Antibodies and fusion proteins binding to CCR8 and uses thereof
WO2021190441A1 (en) * 2020-03-23 2021-09-30 倍而达药业（苏州）有限公司 Cd47/humanized cd47 antibody or antigen binding fragment or immunologically active fragment thereof and use thereof
CA3172449A1 (en) 2020-03-27 2021-09-30 Erik Hans MANTING Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
TW202144407A (en) * 2020-04-02 2021-12-01 大陸商正大天晴藥業集團股份有限公司 Antigen-binding polypeptide binding to cd47, and use thereof
CN111635459B (en) * 2020-06-27 2021-01-15 广东赛尔生物科技有限公司 anti-CD 47 antibodies and their use in treating cancer
JP2023550544A (en) 2020-11-03 2023-12-01 アールディスカバリー エルエルシー Therapy for the treatment of cancer and diseases associated with phagocytosis deficiency
AU2021376354A1 (en) 2020-11-04 2023-06-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
KR20230142828A (en) * 2020-11-04 2023-10-11 더 트러스티즈 오브 다트마우스 칼리지 VISTA agonists for the treatment/prevention of ischemic and/or reperfusion injury
JP2023552375A (en) 2020-12-06 2023-12-15 エーエルエックス オンコロジー インコーポレイテッド Multimers for reducing interference of drugs that bind to CD47 in serological assays
WO2022130016A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
CN116964095A (en) * 2021-02-19 2023-10-27 沙裴隆有限公司 Single domain antibodies against CD47 and uses thereof
KR20230157388A (en) 2021-03-12 2023-11-16 멘두스 비.브이. Methods of vaccination and uses of CD47 blockade
CN112979764B (en) * 2021-03-26 2022-08-02 复旦大学附属中山医院 Polypeptide specifically binding to human CD47 molecule and application thereof
TW202302145A (en) 2021-04-14 2023-01-16 美商基利科學股份有限公司 Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
KR20240025616A (en) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 Diacylglycerol Kinase Modulating Compounds
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022297367A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240091056A (en) 2021-10-28 2024-06-21 길리애드 사이언시즈, 인코포레이티드 Pyridizine-3(2H)-one derivatives
CN118201941A (en) 2021-10-29 2024-06-14 吉利德科学公司 CD73 compounds
CA3239528A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022417491A1 (en) 2021-12-22 2024-05-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
WO2023159220A1 (en) * 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (en) 2022-04-05 2023-12-01 美商基利科學股份有限公司 Combination therapy for treating colorectal cancer
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751908T2 (en) 1986-07-07 1997-02-06 Centocor Inc Murine-human chimeric immunoglobulin, specific for tumor-associated 17-1A antigen
CA2303072A1 (en) 1997-09-11 1999-03-18 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7531643B2 (en) 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
CA2226962A1 (en) * 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
DE19813759C1 (en) 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Inducing a natural killer cell immune response ex vivo
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
WO2000053634A1 (en) 1999-03-10 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Single-stranded fv inducing apoptosis
JP2004513066A (en) * 1999-06-21 2004-04-30 インカイン　ファーマシューティカル　カンパニー，インコーポレイティド Angiosidine: CYS-SER-VAL-THR-CYS-GLY specific tumor cell adhesion receptor
US20010041670A1 (en) * 1999-12-06 2001-11-15 Ronit Simantov Thrombospondin-binding region of histidine-rich glycoprotein and method of use
EP1519735A4 (en) 2001-12-12 2006-01-11 Conforma Therapeutic Corp Assays and implements for determining and modulating hsp90 binding activity
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
CN101133083A (en) 2003-11-11 2008-02-27 中外制药株式会社 Humanized anti-cd47 antibody
WO2006031653A2 (en) 2004-09-10 2006-03-23 Wyeth Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
JP2007008895A (en) 2005-07-04 2007-01-18 Chugai Pharmaceut Co Ltd Combined use of anti-cd47 antibody and integrin ligand
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
MX2008011492A (en) 2006-03-10 2008-09-22 Wyeth Corp Anti-5t4 antibodies and uses thereof.
WO2008043072A2 (en) 2006-10-05 2008-04-10 Biogen Idec Inc. Cd80 antagonists for treating neoplastic disorders
CA3163418A1 (en) * 2006-10-06 2008-05-22 Jeffrey S. Isenberg Prevention of tissue ischemia, related methods and compositions
AU2014201010B2 (en) 2008-01-15 2016-03-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
CA3054220C (en) 2008-01-15 2022-10-11 The Board Of Trustees Of The Leland Stanford Junior University Methods for manilpulating phagocytosis mediated by cd47
CA2965198C (en) 2008-01-15 2021-02-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
JP2011512332A (en) 2008-02-11 2011-04-21 キュアー テック リミテッド Monoclonal antibodies for tumor therapy
KR101604515B1 (en) 2008-03-14 2016-03-17 알러간, 인코포레이티드 Immuno-Based Botulinum Toxin Serotype A Activity Assays
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
US8951527B2 (en) 2008-08-07 2015-02-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radioprotectants targeting thrombospondin-1 and CD47
SI2477648T1 (en) 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
CN102812041A (en) 2010-01-21 2012-12-05 英穆尔诺基公司 Compositions and Methods for Treatment of Ovarian Cancer
PL3789038T3 (en) * 2010-05-14 2023-01-23 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
US20140271683A1 (en) 2010-12-21 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor
EP2812443B1 (en) * 2012-02-06 2019-05-29 Inhibrx, Inc. Cd47 antibodies and methods of use thereof
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
CN104024276A (en) 2012-06-21 2014-09-03 卡姆普根有限公司 LSR antibodies, and uses thereof for treatment of cancer
ES2784631T3 (en) 2012-12-03 2020-09-29 Novimmune Sa Anti-CD47 antibodies and methods of using them
KR20150093770A (en) 2012-12-12 2015-08-18 베스쿨럭스 인코포레이티드 Therapeutic cd47 antibodies
US9221908B2 (en) * 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
SG11201506132PA (en) 2013-02-06 2015-09-29 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
ES2728066T3 (en) 2013-03-15 2019-10-22 Univ Leland Stanford Junior Methods for obtaining therapeutically effective doses of anti-CD47 agents
CN103665165B (en) 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 Bi-specific antibody of a kind of targeted human CD47-SIRP signal α path and its production and use
EP3089993A1 (en) 2013-12-31 2016-11-09 Development Center for Biotechnology Anti-vegf antibodies and use thereof
EP3349787A4 (en) 2015-09-18 2019-03-27 Arch Oncology, Inc. Therapeutic cd47 antibodies
US10946042B2 (en) 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
US20190309066A1 (en) 2017-03-22 2019-10-10 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers
EP3600393A4 (en) 2017-03-22 2020-12-23 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers

Also Published As

Publication number Publication date
AU2013359167B2 (en) 2018-08-23
NZ708445A (en) 2020-10-30
CN105102479B (en) 2019-06-28
WO2015191861A1 (en) 2015-12-17
US20140363442A1 (en) 2014-12-11
US10676524B2 (en) 2020-06-09
US20150274826A1 (en) 2015-10-01
MX2015007446A (en) 2015-12-07
AU2013359167A1 (en) 2015-06-11
BR112015013431A2 (en) 2017-11-14
US10669336B2 (en) 2020-06-02
HK1216647A1 (en) 2016-11-25
EP2931751A2 (en) 2015-10-21
CN105102479A (en) 2015-11-25
WO2014093678A3 (en) 2014-11-27
EP2931751A4 (en) 2016-07-13
JP2016501892A (en) 2016-01-21
US20180051081A1 (en) 2018-02-22
JP6572131B2 (en) 2019-09-04
ES2786083T3 (en) 2020-10-08
KR20150093770A (en) 2015-08-18
PH12015501318A1 (en) 2015-08-24
US20180057592A1 (en) 2018-03-01
EP2931751B1 (en) 2020-02-05
RU2015122228A (en) 2017-01-19
CA2894439A1 (en) 2014-06-19
IL239339A0 (en) 2015-07-30
WO2014093678A2 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
HUS2400016I1 (en) Anti-fcrn antibodies
HK1216647A1 (en) Therapeutic cd47 antibodies cd47
IL264558A (en) Anti-il-23p19 antibodies
HK1204571A1 (en) Protease-regulated antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
IL229254A0 (en) Therapeutic antibodies
EP2844290A4 (en) Novel antibodies
EP2837685A4 (en) Anti-fgfr2 antibody
EP2826790A4 (en) Gremlin-1 antibody
HK1210186A1 (en) Anti-h7cr antibodies h7cr
PL2935330T3 (en) Anti-notch3 antibodies
EP2804876A4 (en) Novel antibodies
EP2811018A4 (en) ANTI-sAPPß ANTIBODY
IL235188A0 (en) Anti-pdgf-c antibodies
ZA201308992B (en) Therapeutic antibodies
GB201209584D0 (en) Modified antibodies
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations